
BjÃ,rn-Tore Gjertsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2087999/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A national precision cancer medicine implementation initiative for Norway. Nature Medicine, 2022, 28, 885-887.	30.7	7
2	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. Leukemia, 2022, , .	7.2	2
3	A cell competition–based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry, 2021, 296, 100179.	3.4	6
4	Temperature-dependent autoactivation associated with clinical variability of <i>PDGFRB</i> Asn666 substitutions. Human Molecular Genetics, 2021, 30, 72-77.	2.9	6
5	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 2021, 13, 672.	3.7	7
6	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Advances, 2021, 5, 1110-1121.	5.2	33
7	Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers, 2021, 13, 755.	3.7	6
8	Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 654817.	2.8	11
9	Preclinical characterisation and development of a novel myelodysplastic syndromeâ€derived cell line. British Journal of Haematology, 2021, 193, 415-419.	2.5	0
10	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells, 2021, 10, 833.	4.1	4
11	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. Cancers, 2021, 13, 1861.	3.7	4
12	FLT3â€ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology, 2021, 15, 2300-2317.	4.6	5
13	Sex disparity in acute myeloid leukaemia with <i>FLT3</i> internal tandem duplication mutations: implications for prognosis. Molecular Oncology, 2021, 15, 2285-2299.	4.6	11
14	Bimodal expression of potential drug target CLLâ€┨ (CLEC12A) on CD34+ blasts of AML patients. European Journal of Haematology, 2021, 107, 343-353.	2.2	5
15	Longâ€ŧerm tolerability and efficacy after initial PegIFNâ€Î± addition to dasatinib in CML P: Fiveâ€year followâ€up of the NordCML007 study. European Journal of Haematology, 2021, 107, 617-623.	2.2	4
16	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. SAGE Open Medical Case Reports, 2021, 9, 2050313X2098841.	0.3	0
17	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica, 2020, 105, 1527-1538.	3.5	19
18	A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. Analytica Chimica Acta, 2020, 1129, 1-11.	5.4	8

#	Article	IF	CITATIONS
19	A Comparison of p53 Isoform Profiles and Apoptosis Induced by Camptothecin or a Herbal Khat Extract (Catha Edulis (Vahl) Forssk. ex Endl.) in Leukemic Cell Lines: Exploring Cellular Responses in Therapy Development. Cancers, 2020, 12, 3596.	3.7	0
20	Single Cell Detection of the p53 Protein by Mass Cytometry. Cancers, 2020, 12, 3699.	3.7	3
21	Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. Frontiers in Pharmacology, 2020, 11, 630.	3.5	9
22	CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine, 2020, 56, 102782.	6.1	14
23	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137.	7.2	47
24	Synthesis of Nâ€Aryl―and Nâ€alkylâ€Substituted Imidazolium Silver Complexes: Cytotoxic Screening by Using Human Cell Lines Modelling Acute Myeloid Leukaemia. ChemMedChem, 2020, 15, 1509-1514.	3.2	7
25	Hit to Leads with Cytotoxic Effect in Leukemic Cells: Total Synthesis Intermediates as a Molecule Treasure Chest. ChemMedChem, 2020, 15, 862-870.	3.2	2
26	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia, 2020, 34, 3186-3196.	7.2	22
27	Tyrosine kinase inhibitorsÂand interferonâ€Î± increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB Journal, 2020, 34, 3773-3791.	0.5	13
28	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 2020, 34, 1751-1759.	7.2	18
29	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica, 2020, 105, 708-720.	3.5	99
30	Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer, 2019, 121, 545-555.	6.4	49
31	Intracellular Signaling in Key Pathways Is Induced by Treatment with Ultrasound and Microbubbles in a Leukemia Cell Line, but Not in Healthy Peripheral Blood Mononuclear Cells. Pharmaceutics, 2019, 11, 319.	4.5	11
32	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncolmmunology, 2019, 8, e1638210.	4.6	19
33	A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma. Annals of Oncology, 2019, 30, v563.	1.2	3
34	Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 2019, 8, 1229.	4.1	18
35	Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S290.	0.4	0
36	Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1729-1749.	2.5	8

#	Article	IF	CITATIONS
37	GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica, 2019, 104, e229-e229.	3.5	4
38	Titrating Complex Mass Cytometry Panels. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 792-796.	1.5	16
39	Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. Scientific Reports, 2019, 9, 5244.	3.3	19
40	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports, 2019, 9, 17471.	3.3	26
41	Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2019, 25, 153-163.	2.0	4
42	Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study. Blood, 2019, 134, 1639-1639.	1.4	5
43	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. Blood, 2019, 134, 2808-2808.	1.4	8
44	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. Blood, 2019, 134, 232-232.	1.4	17
45	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2019, 134, 2547-2547.	1.4	5
46	Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. Blood, 2019, 134, 2936-2936.	1.4	0
47	Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study. Blood, 2019, 134, 3943-3943.	1.4	1
48	Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics, 2018, 173, 32-41.	2.4	11
49	Clobal Gene Expression Response in Peripheral Blood Cells of Petroleum Workers Exposed to Sub-Ppm Benzene Levels. International Journal of Environmental Research and Public Health, 2018, 15, 2385.	2.6	7
50	Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring – a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer, 2018, 119, 1028-1035.	6.4	7
51	Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine. Scientific Reports, 2018, 8, 11118.	3.3	44
52	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	7.2	184
53	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood, 2018, 132, 264-264.	1.4	5
54	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS. Blood, 2018, 132, 2672-2672.	1.4	5

#	Article	IF	CITATIONS
55	A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy. Blood, 2018, 132, 1502-1502.	1.4	1
56	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 2017, 129, 1636-1645.	1.4	77
57	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica, 2017, 102, 1361-1367.	3.5	28
58	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1543-1554.	2.5	20
59	In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer Journal, 2017, 7, e604-e604.	6.2	22
60	NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia, 2017, 31, 2264-2267.	7.2	4
61	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia, 2017, 31, 301-309.	7.2	61
62	Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release, 2017, 245, 70-80.	9.9	31
63	Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in Medicine, 2017, 4, 211.	2.6	28
64	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer, 2017, 17, 630.	2.6	18
65	Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML). Oncotarget, 2017, 8, 7946-7963.	1.8	41
66	Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death and Disease, 2016, 7, e2497-e2497.	6.3	17
67	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clinical Cancer Research, 2016, 22, 4030-4038.	7.0	20
68	Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia, 2016, 30, 1853-1860.	7.2	60
69	Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research, 2016, 113, 216-227.	7.1	15
70	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release, 2016, 243, 172-181.	9.9	332
71	Single-cell proteomics: potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics, 2016, 16, 579-589.	3.1	26
72	BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles. Blood, 2016, 128, 592-592.	1.4	1

#	Article	IF	CITATIONS
73	The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS ONE, 2016, 11, e0158208.	2.5	28
74	Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget, 2016, 7, 8105-8118.	1.8	19
75	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood, 2016, 128, 3995-3995.	1.4	1
76	Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment. Blood, 2016, 128, 3069-3069.	1.4	0
77	Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia. Blood, 2016, 128, 32-32.	1.4	14
78	Effects of Dasatinib and Interferon-Î \pm Combination Treatment on the Immune System in CML. Blood, 2016, 128, 627-627.	1.4	0
79	4â€Alkylated Silver–Nâ€Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells. ChemMedChem, 2015, 10, 1522-1527.	3.2	28
80	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget, 2015, 6, 2794-2811.	1.8	13
81	Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology, Immunotherapy, 2015, 64, 337-347.	4.2	67
82	Interactions of the Natural Product (+)-Avrainvillamide with Nucleophosmin and Exportin-1 Mediate the Cellular Localization of Nucleophosmin and its AML-Associated Mutants. ACS Chemical Biology, 2015, 10, 855-863.	3.4	21
83	Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phaseâ€2 study (<scp>N</scp> ord <scp>CML</scp> 006). European Journal of Haematology, 2015, 94, 243-250.	2.2	61
84	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia, 2015, 29, 11-19.	7.2	171
85	Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients. Blood, 2015, 126, 477-477.	1.4	1
86	Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology, 2015, 17, 20-29.	1.6	4
87	Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study. Blood, 2015, 126, 4022-4022.	1.4	Ο
88	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. Blood, 2015, 126, 4931-4931.	1.4	0
89	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867.	1.4	0
90	Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions. Journal of Clinical Medicine, 2014, 3, 1466-1489.	2.4	8

#	Article	IF	CITATIONS
91	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma, 2014, 55, 2114-2119.	1.3	11
92	SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. Cell Stem Cell, 2014, 15, 431-446.	11.1	187
93	Performance of superâ€SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics, 2014, 14, 1971-1976.	2.2	32
94	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1738-1742.	7.2	90
95	Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta. PLoS ONE, 2014, 9, e88632.	2.5	10
96	First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma. PLoS ONE, 2014, 9, e89527.	2.5	20
97	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunology, Immunotherapy, 2013, 62, 773-785.	4.2	88
98	Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation, 2013, 20, 1124-1124.	11.2	30
99	The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics, 2013, 5, 13.	4.1	45
100	Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics, 2013, 5, 12.	4.1	79
101	Nitroreductase, a Near-Infrared Reporter Platform for <i>In Vivo</i> Time-Domain Optical Imaging of Metastatic Cancer. Cancer Research, 2013, 73, 1276-1286.	0.9	38
102	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs, 2013, 22, 551-563.	4.1	28
103	Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia, 2013, 27, 1520-1526.	7.2	60
104	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	9.4	334
105	Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death and Disease, 2013, 4, e516-e516.	6.3	29
106	Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood, 2013, 121, e34-e42.	1.4	21
107	Pharmacological Inhibition Of The SIRT1 Deacetylase With The Small Molecule Inhibitor Tenovin-6 Enhances Ablation Of FLT3-ITD+ LSC In Combination With TKI Treatment. Blood, 2013, 122, 2685-2685.	1.4	1
108	Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53null Cell Lines. PLoS ONE, 2013, 8, e56276.	2.5	26

#	Article	IF	CITATIONS
109	Single Cell Analysis Of Protein Phosphorylation In Chronic Myeloid Leukemia Treated With Dasatinib, Eltrombopag, and Pegfilgrastim. Blood, 2013, 122, 1492-1492.	1.4	0
110	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	1.4	0
111	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. Blood, 2013, 122, 2625-2625.	1.4	1
112	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 1485-1485.	1.4	0
113	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 2731-2731.	1.4	0
114	Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy. Blood, 2013, 122, 649-649.	1.4	0
115	Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. , 2012, , .		0
116	Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1116-1124.	3.0	9
117	Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics, 2012, 76, 69-78.	2.4	8
118	Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia, 2012, 26, 910-917.	7.2	77
119	Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene, 2012, 31, 1533-1545.	5.9	52
120	Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation, 2012, 19, 1381-1389.	11.2	34
121	Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Expert Review of Proteomics, 2012, 9, 595-598.	3.0	20
122	Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. Expert Opinion on Investigational Drugs, 2012, 21, 587-603.	4.1	23
123	Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology, 2012, 28, 201-212.	5.3	8
124	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with <i>FLT3</i> mutation status – consequences and potentials for pharmacological intervention. British Journal of Haematology, 2012, 156, 468-480.	2.5	39
125	Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation, 2012, 42, 1016-1026.	3.4	2
126	Diseaseâ€stabilizing treatment with allâ€trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and antiâ€leukemic treatment. American Journal of Hematology, 2012, 87, 368-376.	4.1	31

BjÃ, rn-Tore Gjertsen

#	Article	IF	CITATIONS
127	Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid. PLoS ONE, 2012, 7, e48992.	2.5	17
128	Humane celler og helseforskningsloven. Tidsskrift for Den Norske Laegeforening, 2012, 132, 540-542.	0.2	1
129	Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy, 2011, 11, 355-357.	2.4	1
130	Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports, 2011, 25, 1549-56.	2.6	33
131	Untangling the intracellular signalling network in cancer — A strategy for data integration in acute myeloid leukaemia. Journal of Proteomics, 2011, 74, 269-281.	2.4	6
132	Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal, 2011, 1, e4-e4.	6.2	23
133	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. Blood, 2011, 118, 1533-1533.	1.4	0
134	Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry, 2010, 111, 574-584.	2.6	40
135	Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia Research, 2010, 34, 77-84.	0.8	9
136	Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology, 2010, 11, 38.	2.2	65
137	Access to the Spleen Microenvironment through Lymph Shows Local Cytokine Production, Increased Cell Flux, and Altered Signaling of Immune Cells during Lipopolysaccharide-Induced Acute Inflammation. Journal of Immunology, 2010, 184, 4547-4556.	0.8	46
138	Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1124-1129.	7.1	503
139	Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases. Hematology, 2010, 15, 338-343.	1.5	22
140	The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity. Toxins, 2010, 2, 174-194.	3.4	58
141	Lentinan: Hematopoietic, Immunological, and Efficacy Studies in a Syngeneic Model of Acute Myeloid Leukemia. Nutrition and Cancer, 2010, 62, 574-583.	2.0	30
142	Clinical proteomics of myeloid leukemia. Genome Medicine, 2010, 2, 41.	8.2	13
143	Hypoxia increases HIF-1α expression andÂconstitutive cytokine release byÂprimary human acute myeloid leukaemia cells. European Cytokine Network, 2010, 21, 154-64.	2.0	36
144	Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs, 2009, 18, 433-455.	4.1	34

#	Article	IF	CITATIONS
145	Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer, 2009, 9, 77.	2.6	18
146	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology, 2009, 625, 6-22.	3.5	22
147	Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology, 2009, 144, 53-68.	2.5	61
148	The protein kinase C agonist PEP005 increases NFâ€ÎºB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology, 2009, 145, 761-774.	2.5	26
149	Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology, 2009, 263, 108-116.	4.2	17
150	Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research, 2009, 33, 276-287.	0.8	13
151	A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research, 2009, 33, 779-787.	0.8	53
152	Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer, 2009, 8, 101.	19.2	42
153	Increased Plasma Colloid Osmotic Pressure Facilitates the Uptake of Therapeutic Macromolecules in a Xenograft Tumor Model. Neoplasia, 2009, 11, 812-822.	5.3	29
154	The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials. Current Cancer Therapy Reviews, 2009, 5, 243-255.	0.3	11
155	Khat induces G1â€phase arrest and increased expression of stressâ€sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences, 2008, 116, 23-30.	1.5	17
156	Review: genetic models of acute myeloid leukaemia. Oncogene, 2008, 27, 3765-3779.	5.9	48
157	Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia, 2008, 22, 287-293.	7.2	56
158	Erythropoietin a safe bet in haemorrhagic shock?. Acta Anaesthesiologica Scandinavica, 2008, 52, 585-586.	1.6	1
159	<i>In vivo</i> biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs, 2008, 17, 1623-1633.	4.1	36
160	Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets, 2008, 8, 666-675.	1.6	18
161	Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood, 2008, 111, 2866-2877.	1.4	35
162	Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia.		3

, 2008, , 161-187.

#	Article	IF	CITATIONS
163	Evaluation of Combinational Therapy of MDM2-Antagonist Nutlin-3 and HDAC-Inhibitor Valproic Acid in Acute Myeloid Leukemia in Vitro and in Vivo. Blood, 2008, 112, 2981-2981.	1.4	0
164	Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica, 2007, 92, 332-341.	3.5	129
165	Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells. Current Pharmaceutical Biotechnology, 2007, 8, 388-400.	1.6	138
166	Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology, 2007, 8, 344-354.	1.6	2
167	Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy. Current Pharmaceutical Biotechnology, 2007, 8, 373-381.	1.6	21
168	Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology, 2007, 12, 199-207.	1.5	14
169	Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy, 2007, 7, 741-751.	2.4	2
170	In Vivo Optical Imaging of Acute Myeloid Leukemia by Green Fluorescent Protein: Time-Domain Autofluorescence Decoupling, Fluorophore Quantification, and Localization. Molecular Imaging, 2007, 6, 7290.2007.00016.	1.4	29
171	Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood, 2007, 109, 2589-2596.	1.4	69
172	Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opinion on Therapeutic Targets, 2007, 11, 1055-1069.	3.4	25
173	LEDCF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer, 2007, 6, 31.	19.2	56
174	Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer, 2007, 6, 33.	19.2	16
175	Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry, 2007, 366, 46-58.	2.4	17
176	The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 2007, 136, 814-828.	2.5	115
177	Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemiaâ€associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology, 2007, 79, 210-225.	2.2	31
178	T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-γ that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology, Immunotherapy, 2007, 56, 913-925.	4.2	25
179	Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation Blood, 2007, 110, 4320-4320.	1.4	0
180	Synergistic Anti-Leukemic Effect of Protein Kinase A Activator and PPARÎ ³ Agonist Is Independent of Bcl-2 Status Blood, 2007, 110, 4200-4200.	1.4	0

#	Article	IF	CITATIONS
181	Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in Acute Myeloid Leukemia Mouse Models Blood, 2007, 110, 4319-4319.	1.4	30
182	Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opinion on Therapeutic Targets, 2006, 10, 51-68.	3.4	42
183	CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation, 2006, 13, 1191-1202.	11.2	46
184	Acute myelogenous leukemia in a patient with Li–Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia, 2006, 20, 734-736.	7.2	15
185	Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research, 2006, 30, 1531-1540.	0.8	53
186	Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 2006, 55, 185-187.	4.2	2
187	Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?. Cancer Immunology, Immunotherapy, 2006, 55, 221-228.	4.2	7
188	Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology, Immunotherapy, 2006, 56, 13-24.	4.2	27
189	Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics, 2006, 7, 198.	2.6	26
190	Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis, 2006, 27, 4086-4095.	2.4	8
191	Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology, 2006, 7, 199-207.	1.6	17
192	Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies. Current Pharmaceutical Biotechnology, 2006, 7, 185-198.	1.6	3
193	Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncológica, 2006, 45, 346-349.	1.8	7
194	A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia. Clinical Cancer Research, 2006, 12, 3985-3992.	7.0	87
195	In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research, 2005, 29, 185-196.	0.8	63
196	Animal models of acute myelogenous leukaemia – development, application and future perspectives. Leukemia, 2005, 19, 687-706.	7.2	66
197	CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. , 2005, 64B, 18-27.		25
198	Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets, 2005, 5, 229-248.	1.6	48

#	Article	IF	CITATIONS
199	Potentiated phospho-protein networks in cancer cells. Breast Cancer Research, 2005, 7, 1.	5.0	1
200	Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy. Current Drug Targets, 2005, 6, 631-646.	2.1	14
201	The Role of Bcl-2 in Apoptosis Induced by khat (Catha Edulis) in Acute Myeloid Leukemia Cell Lines Blood, 2005, 106, 4469-4469.	1.4	Ο
202	Characterization of Ribosomal P Autoantibodies in Relation to Cell Destruction and Autoimmune Disease. Scandinavian Journal of Immunology, 2004, 60, 189-198.	2.7	14
203	Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia, 2004, 18, 1989-1996.	7.2	33
204	How should clinical data be included in experimental studies of cancer immunology?. Cancer Immunology, Immunotherapy, 2004, 53, 677-80.	4.2	2
205	Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer, 2004, 91, 1726-1734.	6.4	53
206	Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells. Cell, 2004, 118, 217-228.	28.9	655
207	Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood, 2004, 103, 2925-2928.	1.4	249
208	Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica, 2004, 89, 391-402.	3.5	72
209	Catha edulis(Khat) Induces Cell Death by Apoptosis in Leukemia Cell Lines. Annals of the New York Academy of Sciences, 2003, 1010, 384-388.	3.8	29
210	Mitochondrial-Targeted Fatty Acid Analog Induces Apoptosis with Selective Loss of Mitochondrial Glutathione in Promyelocytic Leukemia Cells. Chemistry and Biology, 2003, 10, 609-618.	6.0	20
211	Irod/Ian5: An Inhibitor of γ-Radiation- and Okadaic Acid-induced Apoptosis. Molecular Biology of the Cell, 2003, 14, 3292-3304.	2.1	59
212	Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica, 2003, 88, 416-28.	3.5	82
213	Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 469-481.	1.8	37
214	Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells. Expert Opinion on Biological Therapy, 2002, 2, 197-210.	3.1	6
215	A Recombinant Adenovirus Expressing Wild-Type Bax Induces Apoptosis in Prostate Cancer Cells Independently of Their Bcl-2 Status and Androgen Sensitivity. Cancer Biology and Therapy, 2002, 1, 163-167.	3.4	30
216	Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplantation, 2002, 29, 165-171.	2.4	35

#	Article	IF	CITATIONS
217	Acute Myelogenous Leukemia with Internal Tandem Duplication of the Flt3 Gene Appearing or Altering at the Time of Relapse: A Report of Two Cases. Leukemia and Lymphoma, 2002, 43, 2027-2029.	1.3	24
218	Expression of Fcε-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics. Leukemia Research, 2002, 26, 515-521.	0.8	5
219	Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica, 2002, 87, 584-95.	3.5	33
220	New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells-The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic Approaches. Stem Cells, 2001, 19, 1-11.	3.2	111
221	Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. British Journal of Haematology, 2001, 115, 79-83.	2.5	100
222	Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. European Journal of Oral Sciences, 2000, 108, 59-69.	1.5	52
223	Induction of Differentiation and Apoptosis— A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia. Oncologist, 2000, 5, 454-462.	3.7	40
224	The effect of heat- and auto-polymerized denture base polymers on clonogenicity, apoptosis, and necrosis in fibroblasts: denture base polymers induce apoptosis and necrosis. Acta Odontologica Scandinavica, 2000, 58, 217-228.	1.6	40
225	Autologous Stem Cell Transplantation As Post-Remission Therapy in Adult Acute Myelogenous Leukemia: Does Platelet Contamination of Peripheral Blood Mobilized Stem Cell Grafts Influence the Risk of Leukemia Relapse?. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 433-443.	1.8	13
226	New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction-Present Use and Future Possibilities. Stem Cells, 2000, 18, 157-165.	3.2	61
227	In VitroCulture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 923-932.	1.8	52
228	Ultrarapid caspase-3 dependent apoptosis induction by serine/threonine phosphatase inhibitors. Cell Death and Differentiation, 1999, 6, 1099-1108.	11.2	117
229	Caspase I-related protease inhibition retards the execution of okadaic acid- and camptothecin-induced apoptosis and PAI-2 cleavage, but not commitment to cell death in HL-60 cells. British Journal of Cancer, 1999, 79, 1685-1691.	6.4	16
230	Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer and Metastasis Reviews, 1998, 17, 345-351.	5.9	18
231	Inherited Mutations in PTEN That Are Associated with Breast Cancer, Cowden Disease, and Juvenile Polyposis. American Journal of Human Genetics, 1997, 61, 1254-1260.	6.2	252
232	Fas/APO-1(CD95)-Induced Apoptosis of Primary Hepatocytes Is Inhibited by cAMP. Biochemical and Biophysical Research Communications, 1997, 232, 20-25.	2.1	68
233	Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology, 1997, 25, 847-855.	7.3	34
234	8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line. British Journal of Cancer, 1995, 72, 1151-1159.	6.4	47

#	Article	IF	CITATIONS
235	Fine Mapping of 28S rRNA Sites Specifically Cleaved in Cells Undergoing Apoptosis. Molecular and Cellular Biology, 1995, 15, 2051-2062.	2.3	112
236	Novel (Rp)-cAMPS Analogs as Tools for Inhibition of cAMP-kinase in Cell Culture. Journal of Biological Chemistry, 1995, 270, 20599-20607.	3.4	219
237	Protein phosphorylation in apoptosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 1995, 1269, 187-199.	4.1	96
238	Sensitive and Rapid Detection of \hat{l}^2 -Galactosidase Expression in Intact Cells by Microinjection of Fluorescent Substrate. Experimental Cell Research, 1995, 219, 372-378.	2.6	12
239	Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. British Journal of Cancer, 1994, 70, 834-840.	6.4	47
240	Microinjected Catalytic Subunit of cAMP-Dependent Protein Kinase Induces Apoptosis in Myeloid Leukemia (IPC-81) Cells. Experimental Cell Research, 1993, 206, 157-161.	2.6	76
241	The genetic subtypes of cAMP-dependent protein kinase — Functionally different or redundant?. Biochimica Et Biophysica Acta - Molecular Cell Research, 1993, 1178, 249-258.	4.1	138
242	Antiapoptotic effect of heterozygously expressed mutant RI (Ala336>Asp) subunit of cAMP kinase I in a rat leukemia cell line. Journal of Biological Chemistry, 1993, 268, 8332-40.	3.4	42
243	The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Experimental Cell Research, 1991, 195, 237-246.	2.6	330
244	Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. Journal of Cellular Physiology, 1991, 146, 73-80.	4.1	114